Progenity’s chief executive officer, Harry Stylli, PhD, will present a corporate overview on Wednesday, December 4, from 1:10 PM to 1:30 PM ET. Dr. Stylli and Eric d’Esparbes, chief financial officer, will also participate in one-on-one meetings with investors.
Progenity, Inc., is a privately held, biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing disease at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.